Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 35-40 , January 2008

Pelvic Lymph Node Irradiation for Prostate Cancer: Who, Why, and When?

  • Dian Wang, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Dian Wang, MD, PhD, Department of Radiation Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226.
    • ,
  • Colleen Lawton, MD

References 

  1. Cooperberg MR, Lubeck DP, Mehta SS, et al. CaPSURE: Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170:S21–S25discussion S26-27 (erratum in J Urol 171:811, 2004)
  2. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146–8151
  3. van den Ouden D, Davidson PJT, Hop W, et al. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol. 1994;151:646–651
  4. Akakura K, Furuya Y, Suzuki H, et al. External beam radiation monotherapy for prostate cancer. Int J Urol. 1999;6:408–413
  5. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 1999;61:1285–1290
  6. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005;23:800–807
  7. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  8. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937–946
  9. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978(erratum in J Clin Oncol 22:386, 2004)
  10. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106
  11. Roach M, DeSilvio C, Lawton CA, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  12. Lawton CA, DeSilvio M, Roach M, et al: An update of the phase III trial comparing whole-Pelvic (WP) to Prostate Only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Updated analysis of RTOG 94-13. Proceedings of the 47th annual ASTRO meeting, Denver, CO, October 16-20, 2005, p. 519
  13. Roach M, DeSilvio M, Valicenti R, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;66:647–653
  14. Gleanson DF, Mellinger GT Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;167:953–958
  15. In:  Greene FL,  Page DL,  Fleming ID, et al. editor. AJCC (American Joint Committee on Cancer)–UICC (Union International Contre Cancer) cancer staging manual. (ed 6). New York, NY: Springer; 2002;
  16. Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol. 1998;16:100–105
  17. Partin AW, Yoo J, Carter B, et al. The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–114
  18. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer (A multi-institutional update). JAMA. 1997;277:1445–1451
  19. Partin AW, Mangold LA, Lamm DA, et al. Contemporary update of prostate cancer staging nomograms (parting tables) for the new millennium. Urology. 2001;58:843–848
  20. Roach M, Marquez C, You H, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1993;28:33–37
  21. Medica M, Giglio M, Germinale F, et al. Roach’s mathematical equations in predicting pathological stage in men with clinically localized prostate cancer. Tumori. 2001;87:13–133
  22. Raghavaiah NV, Jordan WP. Prostatic lymphography. J Urol. 1979;121:178–181
  23. Cerny JC, Farah R, Rian R, et al. An evaluation of lymphangiography in staging carcinoma of prostate. J Urol. 1975;113:367–370
  24. Brossner C, Ringhofer H, Hernady T, et al. Lymphatic drainage of prostatic transition and peripheral zones visualized on a three-dimensional workstation. Urology. 2001;57:389–393
  25. Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol. 1997;158:1891–1894
  26. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167:1681–1686
  27. Wawroschek F, Vogt H, Wengenmair H, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Urol Int. 2003;70:303–310
  28. Bader P, Burkhard FC, Markwalder R, et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy (Is there a chance to cure?). J Urol. 2003;169:849–854
  29. Tenaglia JL, Iannucci M. Extended pelvic lymphadenectomy for the treatment of localized prostate carcinoma. Eur Urol Today. 2004;15:
  30. Clark T, Parekh DJ, Cookson MS, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169:145–148
  31. Lee N, Newhouse JH, Olsson CA, et al. Which patients with newly diagnosed prostate cancer need a CT scan of the abdomen and pelvis? (An analysis of 588 patients). Urology. 1999;54:490–494
  32. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–2127
  33. Wolf JS, Cher M, Dall’era M, et al. The use and accuracy of cross- sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995;153:993–999
  34. Villiers GM, Verstraete KL, DeNeve WJ, et al. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol. 2005;76:99–106
  35. Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994–998
  36. Albrecht S, Buchegger F, Soloviev D, et al. C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007;34:185–196
  37. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1389
  38. Harisinghani MG, Barentsz JO, Hahn PR, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–2499(erratum in N Engl J Med 349:1010, 2003)
  39. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Eng J Med. 1997;337:949–955
  40. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Eng J Med. 1991;324:709–715
  41. Bagshaw MA, Pistenma DA, Ray GR, et al. Evaluation of extended field radiotherapy for prostatic neoplasms: 1976 progress report. Cancer Treat Rep. 1977;61:297–306
  42. McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1981;7:1333–1339
  43. Polysongsang SS, Aron BS, Shehata WM. Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate?. Urology. 1991;40:18–26
  44. Seaward SA, Weinberg V, Lewis P, et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:1055–1062
  45. Seaward SA, Weinberg V, Lewis P, et al. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am. 1998;4:370–377
  46. Pan CC, Kim KY, Taylor JM, et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53:1139–1145
  47. Aristizabal SA, Steinbronn D, Heusinkveld RS. External beam radiotherapy in cancer of the prostate (The University of Arizona experience). Radiother Oncol. 1984;1:309–315
  48. Rosen E, Cassady JR, Connolly J, et al. Radiotherapy for prostate carcinoma: the JCRT experience (1968-1978) (II. Factors related to tumor control and complications). Int J Radiat Oncol Biol Phys. 1985;11:725–730
  49. Zagars GK, von Eschenbach AC, Johnson DE, et al. Stage C adenocarcinoma of the prostate (An analysis of 551 patients treated with external beam radiation). Cancer. 1987;60:1489–1499
  50. Asbell SO, Krall JM, Pilepich MV, et al. Elective pelvic irradiation in stage A2 (B carcinoma of the prostate: analysis of RTOG 77-06). Int J Radiat Oncol Biol Phys. 1988;15:1307–1316
  51. Asbell SO, Martz KL, Shin KH, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1bN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998;40:769–782
  52. Forman JD, Lee Y, Roberson P, et al. Advantages of CT and beam’s eye view display to confirm the accuracy of pelvic lymph node irradiation in carcinoma of the prostate. Radiology. 1993;186:889–892
  53. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  54. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  55. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  56. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 2000;46:165–172
  57. Li XA, Wang JZ, Jursinic PA, et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:1251–1257
  58. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  59. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  60. Wang JZ, Li XA, Yu CX, et al. The low alpha/beta ratio for prostate cancer (What does the clinical outcome of HDR brachytherapy tell us?). Int J Radiat Oncol Biol Phys. 2003;57:1101–1108
  61. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827

PII: S1053-4296(07)00077-X

doi: 10.1016/j.semradonc.2007.09.005

Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 35-40 , January 2008

Article Tools